J. Clemmesen, Statistical studies in the aetiology of malignant neoplasms, Acta Pathol. Microbiol. Scand, vol.3, issue.209S1, pp.1-58, 1969.

D. Trichopoulos, B. Macmahon, and P. Cole, Menopause and breast cancer risk, J. Natl. Cancer Inst, vol.48, issue.3, pp.605-613, 1972.

R. C. Travis and T. J. Key, Oestrogen exposure and breast cancer risk, Breast Cancer Research, vol.81, issue.Suppl 3, pp.239-247, 2003.
DOI : 10.1186/bcr628
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC314432

A. Micheli, P. Muti, G. Secreto, V. Krogh, E. Meneghini et al., Endogenous sex hormones and subsequent breast cancer in premenopausal women, International Journal of Cancer, vol.26, issue.2, pp.312-318, 2004.
DOI : 10.1002/ijc.20403

G. Secreto and B. Zumoff, Abnormal production of androgens in women with breast cancer, Anticancer Res, vol.14, pp.5-2113, 1994.

T. J. Key and M. C. Pike, The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer, European Journal of Cancer and Clinical Oncology, vol.24, issue.1, pp.29-43, 1988.
DOI : 10.1016/0277-5379(88)90173-3

J. Lewis, K. Manson, J. Margolis, M. J. Ockene, L. O-"-sullivan et al., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women " s Health Initiative randomized controlled trial, JAMA, vol.291, issue.14, pp.1701-1712, 2004.

C. M. Viscoli, L. M. Brass, W. N. Kernan, P. M. Sarrel, S. Suissa et al., A clinical trial of estrogenreplacement therapy after ischemic stroke, N. Engl. J. Med, issue.17, pp.345-1243, 2001.

R. K. Ross, A. Paganini-hill, P. C. Wan, and M. C. Pike, Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin, Journal of the National Cancer Institute, vol.92, issue.4, pp.328-332, 2000.
DOI : 10.1093/jnci/92.4.328

P. G. Moorman, H. Kuwabara, R. C. Millikan, and B. Newman, Menopausal hormones and breast cancer in a biracial population, Am. J. Public Health, vol.90, issue.6, pp.966-971, 2000.

C. L. Chen, N. S. Weiss, P. Newcomb, W. Barlow, and E. White, Hormone Replacement Therapy in Relation to Breast Cancer, JAMA, vol.287, issue.6, pp.734-741, 2002.
DOI : 10.1001/jama.287.6.734

J. V. Porch, I. M. Lee, N. R. Cook, K. M. Rexrode, and J. E. Burin, Estrogen-progestin replacement therapy and breast cancer risk: the Women " s Health Study (United States), Cancer Causes Contr, pp.847-854, 2002.

L. K. Weiss, R. T. Burkman, K. L. Cushing-haugen, L. F. Voigt, M. S. Simon et al., Hormone Replacement Therapy Regimens and Breast Cancer Risk, Obstetrics & Gynecology, vol.100, issue.6, pp.1148-1158, 2002.
DOI : 10.1097/00006250-200212000-00003

C. I. Li, K. E. Malone, P. L. Porter, N. S. Weiss, M. T. Tang et al., Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer, JAMA, vol.289, issue.24, pp.3254-3263, 2003.
DOI : 10.1001/jama.289.24.3254

H. L. Olsson, C. Ingvar, and A. Bladstrom, Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden, Cancer, vol.336, issue.6, pp.1387-1392, 2003.
DOI : 10.1002/cncr.11205

V. Beral, Breast cancer and hormone-replacement therapy: the Million Women Study, The Lancet, vol.362, issue.9392, pp.419-427, 2003.
DOI : 10.1016/S0140-6736(03)14596-5

P. A. Newcomb, L. Titus-ernstoff, K. M. Egan, A. Trentham-dietz, J. A. Baron et al., Postmenopausal estrogen and progestin use in relation to breast cancer risk, Cancer Epidemiol. Biomarkers Prev, vol.11, issue.7, pp.593-600, 2002.

C. Schairer, J. Lubin, R. Troisi, S. Sturgeon, L. Brinton et al., Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk, JAMA, vol.283, issue.4, pp.485-491, 2000.
DOI : 10.1001/jama.283.4.485

R. T. Chlebowski, S. L. Hendrix, R. D. Langer, M. L. Stefanick, M. Gass et al., Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women, JAMA, vol.289, issue.24, pp.3243-3253, 2003.
DOI : 10.1001/jama.289.24.3243

S. Hulley, C. Furberg, E. Barrett-connor, J. Cauley, D. Grady et al., Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy, JAMA, vol.288, issue.1, pp.58-66, 2002.
DOI : 10.1001/jama.288.1.58

M. C. Pike and R. K. Ross, Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer, Steroids, vol.65, issue.10-11, pp.10-11, 2000.
DOI : 10.1016/S0039-128X(00)00122-7

R. J. Santen, J. Pinkerton, C. Mccartney, and G. R. Petroni, Risk of Breast Cancer with Progestins in Combination with Estrogen as Hormone Replacement Therapy, The Journal of Clinical Endocrinology & Metabolism, vol.86, issue.1, pp.16-23, 2001.
DOI : 10.1210/jcem.86.1.7269

C. Stahlberg, A. T. Pederson, E. Lynge, and B. Ottesen, Hormone replacement therapy and risk of breast cancer: the role of progestins, Acta Obstetricia et Gynecologica Scandinavica, vol.15, issue.7, pp.335-344, 2003.
DOI : 10.1016/S1043-2760(97)00122-7

A. Fournier, F. Berrino, E. Riboli, V. Avenel, and F. , Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort, International Journal of Cancer, vol.158, issue.3, pp.448-454, 2005.
DOI : 10.1002/ijc.20710
URL : https://hal.archives-ouvertes.fr/inserm-00129104

D. Grady, T. Gebretsadik, K. Kerlikowske, V. Ernster, and D. Petitti, Hormone replacement therapy and endometrial cancer risk: A meta-analysis, Obstetrics & Gynecology, vol.85, issue.2, pp.304-313, 1995.
DOI : 10.1016/0029-7844(94)00383-O

K. L. Cushing, N. S. Weiss, L. F. Voigt, B. Mcknight, and S. A. Beresford, Risk of Endometrial Cancer in Relation to Use of Low-Dose, Unopposed Estrogens, Obstetrics & Gynecology, vol.91, issue.1, pp.35-39, 1998.
DOI : 10.1016/S0029-7844(97)00577-2

T. Writing-group-for-the, . Pepi, and . Trial, Effects of hormone replacement therapy on endometrial histology in postmenopausal, women. The Postmenopausal Estrogen/Progestin Interventions (PEPI), Trial, JAMA, vol.275, issue.5, pp.370-375, 1996.

J. E. Rossouw, G. L. Anderson, R. L. Prentice, A. Z. Lacroix, C. Kooperberg et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women " s Health Initiative randomized controlled trial, JAMA, vol.288, issue.3, pp.321-333, 2002.

C. Campagnoli, L. Lesca, C. Cantamessa, and C. , Long-term hormone replacement treatment in menopause: new choices, old apprehensions, recent findings, Maturitas, vol.18, issue.1, pp.21-46, 1993.
DOI : 10.1016/0378-5122(93)90027-F

L. A. Mattsson, G. Cullberg, and G. Samsioe, Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints, Maturitas, vol.4, issue.2, pp.95-102, 1982.
DOI : 10.1016/0378-5122(82)90035-4

U. Omodei and L. Speroff, Outlook on continuous oestrogen-progestin therapy, Contemp, Obstet. Gynecol, pp.31-171, 1988.

M. Doren, G. Reuther, H. W. Minne, and H. P. Schneider, Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women, American Journal of Obstetrics and Gynecology, vol.173, issue.5, pp.1446-1451, 1995.
DOI : 10.1016/0002-9378(95)90631-2

R. G. Hahn, Compliance considerations with estrogen replacement: Withdrawal bleeding and other factors, American Journal of Obstetrics and Gynecology, vol.161, issue.6, pp.1854-1858, 1989.
DOI : 10.1016/S0002-9378(89)80006-7

H. Jernstrom, P. O. Bendahl, J. Lidfeldt, C. Nerbrand, C. D. Agardh et al., A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women " s health in the Lund area (WHILA) study (Sweden), Cancer Causes Contr, pp.14-673, 2003.

C. Magnusson, J. A. Baron, N. Correia, R. Bergstrom, and H. , Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy, International Journal of Cancer, vol.4, issue.3, pp.339-344, 1999.
DOI : 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6

C. Stahlberg, A. T. Pedersen, E. Lynge, Z. J. Andersen, N. Keiding et al., Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe, International Journal of Cancer, vol.76, issue.5, pp.721-727, 2004.
DOI : 10.1002/ijc.20016

D. L. Moyer, B. De-lignieres, P. Driguez, and J. P. Pez, Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes**Supported in part by Besins-Iscovesco Laboratories, Paris, France., Fertility and Sterility, vol.59, issue.5, pp.992-997, 1993.
DOI : 10.1016/S0015-0282(16)55916-0

J. Y. Gillet, G. Andre, B. Faguer, R. Erny, M. Buvat-herbaut et al., Induction of amenorrhea during hormone replacement therapy: Optimal micronized progesterone dose. A multicenter study, Maturitas, vol.19, issue.2, pp.103-115, 1994.
DOI : 10.1016/0378-5122(94)90060-4

T. L. Alberg, G. W. Bush, G. B. Comstock, S. R. Gordon, C. Miller et al., Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women, J. Natl. Cancer Inst, pp.95-1218, 2003.

K. Kerlikowske, D. L. Miglioretti, R. Ballard-barbash, D. L. Weaver, D. S. Buist et al., Prognostic Characteristics of Breast Cancer Among Postmenopausal Hormone Users in a Screened Population, Journal of Clinical Oncology, vol.21, issue.23, pp.4314-4321, 2003.
DOI : 10.1200/JCO.2003.05.151

W. C. Willett, G. Colditz, and M. Stampfer, Postmenopausal Estrogens???Opposed, Unopposed, or None of the Above, JAMA, vol.283, issue.4, pp.534-535, 2000.
DOI : 10.1001/jama.283.4.534

B. De-lignières, F. De-vathaire, S. Fournier, R. Urbinelli, F. Allaert et al., Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women, Climacteric, vol.86, issue.4, pp.332-340, 2002.
DOI : 10.1161/01.ATV.17.11.3071

J. A. Simon, D. E. Robinson, M. C. Andrews, J. R. Hildebrand, I. et al., The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone*???*Supported in part by a grant from Besins-Iscovesco, Paris, France.???Presented in part at the 35th Annual Meeting of the Society for Gynecologic Investigation, Baltimore, Maryland, March 17 to 20, 1988., Fertility and Sterility, vol.60, issue.1, pp.26-33, 1993.
DOI : 10.1016/S0015-0282(16)56031-2

M. I. Whitehead and D. Fraser, The effects of estrogens and progestogens on the endometrium. Modern approach to treatment, Obstet. Gynecol. Clin. North Am, vol.14, issue.1, pp.299-320, 1987.

S. A. Pasquale, G. A. Bachmann, R. G. Foldesy, R. E. Blackwell, and J. P. Levine, Peripheral progesterone (P) levels and endometrial response to various dosages of vaginally administered P in estrogen-primed women, Fertility and Sterility, vol.68, issue.5, pp.810-815, 1997.
DOI : 10.1016/S0015-0282(97)00329-4

J. Russo, M. H. Lareef, Q. Tahin, Y. F. Hu, C. Slater et al., 17??-Estradiol is carcinogenic in human breast epithelial cells, The Journal of Steroid Biochemistry and Molecular Biology, vol.80, issue.2, pp.149-162, 2002.
DOI : 10.1016/S0960-0760(01)00183-2

J. Russo and I. H. Russo, Genotoxicity of steroidal estrogens, Trends in Endocrinology & Metabolism, vol.15, issue.5, pp.211-214, 2004.
DOI : 10.1016/j.tem.2004.05.007

C. A. Lange, J. K. Richer, and K. B. Horwitz, Hypothesis: Progesterone Primes Breast Cancer Cells for Cross-Talk with Proliferative or Antiproliferative Signals, Molecular Endocrinology, vol.13, issue.6, pp.829-836, 1999.
DOI : 10.1210/mend.13.6.0290

E. A. Musgrove, C. S. Lee, and R. L. Sutherland, Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, cfos , and c-myc genes, Mol. Cell. Biol, issue.10, pp.11-5032, 1991.

R. L. Sutherland, C. S. Lee, R. S. Feldman, and E. A. Musgrove, Regulation of breast cancer cell cycle progression by growth factors, steroids and steroid antagonists, The Journal of Steroid Biochemistry and Molecular Biology, vol.41, issue.3-8, pp.3-8, 1992.
DOI : 10.1016/0960-0760(92)90357-O

R. L. Sutherland, O. W. Prall, C. K. Watts, and E. A. Musgrove, Estrogen and progestin regulation of cell cycle progression, Journal of Mammary Gland Biology and Neoplasia, vol.3, issue.1, pp.63-72, 1998.
DOI : 10.1023/A:1018774302092

B. De-lignières, Effects of progestogens on the postmenopausal breast, Climacteric, vol.72, issue.3, pp.229-235, 2002.
DOI : 10.1016/S0029-7844(97)00212-3

J. Eden, Progestins and breast cancer, American Journal of Obstetrics and Gynecology, vol.188, issue.5, pp.1123-1131, 2003.
DOI : 10.1067/mob.2003.201

J. R. Pasqualini, J. Paris, R. Sitruk-ware, G. Chetrite, and J. Botella, Progestins and breast cancer, J. Steroid Biochem. Mol. Biol, vol.65, pp.1-6, 1998.

D. J. Ferguson and T. J. Anderson, Morphological evaluation of cell turnover in relation to the menstrual cycle in the ???resting??? human breast, British Journal of Cancer, vol.44, issue.2, pp.177-181, 1981.
DOI : 10.1038/bjc.1981.168

T. A. Longacre and S. A. Bartow, A Correlative Morphologic Study of Human Breast and Endometrium in the Menstrual Cycle, The American Journal of Surgical Pathology, vol.10, issue.6, pp.382-393, 1986.
DOI : 10.1097/00000478-198606000-00003

L. Dahmoush, M. C. Pike, and M. F. Press, Hormones and breast cell proliferation Treatment of the postmenopausal women: basic and clinic aspects, pp.325-337, 1994.

L. J. Hofseth, A. M. Raafat, J. R. Osuch, D. R. Pathak, C. A. Slomski et al., Hormone Replacement Therapy with Estrogen or Estrogen plus Medroxyprogesterone Acetate Is Associated with Increased Epithelial Proliferation in the Normal Postmenopausal Breast, Journal of Clinical Endocrinology & Metabolism, vol.84, issue.12, pp.4559-4565, 1999.
DOI : 10.1210/jc.84.12.4559

C. Johansson, T. J. Anderson, R. Bergstrom, A. Lindgren, and R. Persson, Epithelial proliferation in the normal human breast in relation to endogenous hormones and oral contraceptive use, The Breast, vol.7, issue.3, pp.162-167, 1998.
DOI : 10.1016/S0960-9776(98)90029-7

H. Olsson, H. Jernstrom, P. Alm, H. Kreipe, C. Ingvar et al., Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factors, Breast Cancer Research and Treatment, vol.266, issue.2, pp.187-196, 1996.
DOI : 10.1007/BF01806214

G. Soderqvist, E. Isaksson, B. Von-schoultz, K. Carlstrom, E. Tani et al., Proliferation of breast epithelial cells in healthy women during the menstrual cycle, American Journal of Obstetrics and Gynecology, vol.176, issue.1, pp.123-128, 1997.
DOI : 10.1016/S0002-9378(97)80024-5

J. Russo, B. A. Gusterson, A. E. Rogers, I. H. Russo, S. R. Wellings et al., Comparative Study of Human and Rat Mammary Tumorigenesis, Lab. Invest, vol.62, issue.3, pp.244-278, 1990.
DOI : 10.1007/978-1-4612-0485-5_15

R. B. Clarke, Human breast cell proliferation and its relationship to steroid receptor expression, Climacteric, vol.14, issue.2, pp.129-137, 2004.
DOI : 10.1006/dbio.2002.0625

I. J. Laidlaw, R. B. Clarke, A. Howell, A. W. Owen, C. S. Potten et al., The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone, Endocrinology, vol.136, issue.1, pp.164-171, 1995.

J. M. Foidart, C. Colin, X. Denoo, J. Desreux, A. Beliard et al., Estradiol and Progesterone Regulate the Proliferation of Human Breast Epithelial Cells, Fertility and Sterility, vol.69, issue.5, pp.963-969, 1998.
DOI : 10.1016/S0015-0282(98)00042-9

B. E. Henderson, M. C. Pike, and J. T. Casagrande, BREAST CANCER AND THE OESTROGEN WINDOW HYPOTHESIS, The Lancet, vol.318, issue.8242, pp.363-364, 1981.
DOI : 10.1016/S0140-6736(81)90675-9

H. Vainio and F. Bianchini, Weight Control and Physical Activity, IARC Handbooks of Cancer Prevention, 2002.

L. Bernstein, J. M. Yuan, R. K. Ross, M. C. Pike, R. Hanisch et al., Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies, Cancer Causes and Control, vol.24, issue.1, pp.51-58, 1990.
DOI : 10.1007/BF00053183

D. Drafta, A. E. Schindler, S. M. Milcu, E. Keller, E. Stroe et al., Plasma hormones in pre- and postmenopausal breast cancer, Journal of Steroid Biochemistry, vol.13, issue.7, pp.793-802, 1980.
DOI : 10.1016/0022-4731(80)90231-9

W. B. Malarkey, L. L. Schroeder, V. C. Stevens, A. G. James, and R. R. Lanese, Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease, Cancer Res, vol.37, issue.12, pp.4655-4659, 1977.

F. Meyer, J. B. Brown, A. S. Morrison, and B. Macmahon, Endogenous Sex Hormones, Prolactin, and Breast Cancer in Premenopausal Women2, JNCI: Journal of the National Cancer Institute, vol.77, issue.3, pp.613-616, 1986.
DOI : 10.1093/jnci/77.3.613

G. Secreto, P. Toniolo, F. Berrino, C. Recchione, S. Di-pietro et al., Increased androgenic activity and breast cancer risk in premenopausal women, Cancer Res, vol.44, issue.12, pp.5902-5905, 1984.

R. Grattarola, The premenstrual endometrial pattern of women with breast cancer.A study of progestational activity, Cancer, vol.4, issue.9, pp.1119-1122, 1964.
DOI : 10.1002/1097-0142(196409)17:9<1119::AID-CNCR2820170904>3.0.CO;2-1

L. Speroff, The meaning of mammographic breast density in users of postmenopausal hormone therapy, Maturitas, vol.41, issue.3, pp.171-175, 2002.
DOI : 10.1016/S0378-5122(02)00006-3

G. A. Greendale, B. A. Reboussin, S. Slone, C. Wasilauskas, M. C. Pike et al., Postmenopausal Hormone Therapy and Change in Mammographic Density, JNCI Journal of the National Cancer Institute, vol.95, issue.1, pp.30-37, 2003.
DOI : 10.1093/jnci/95.1.30

A. M. Oza and N. F. Boyd, Mammographic Parenchymal Patterns: A Marker of Breast Cancer Risk, Epidemiologic Reviews, vol.15, issue.1, pp.196-208, 1993.
DOI : 10.1093/oxfordjournals.epirev.a036105

M. J. Chiarelli, J. L. Yaffe, and . Hopper, Heritability of mammographic density, a risk factor for breast cancer, N. Engl. J. Med, vol.347, issue.12, pp.886-894, 2002.

C. Byrne, G. A. Colditz, W. C. Willett, F. E. Speizer, M. Pollak et al., Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density, Cancer Res, issue.14, pp.60-3744, 2000.

N. F. Boyd, C. Greenberg, G. Lockwood, L. Little, L. Martin et al., Effects at Two Years of a Low-Fat, High-Carbohydrate Diet on Radiologic Features of the Breast: Results From a Randomized Trial, JNCI Journal of the National Cancer Institute, vol.89, issue.7, pp.488-496, 1997.
DOI : 10.1093/jnci/89.7.488

R. T. Chlebowski and A. Mctiernan, Biological Significance of Interventions That Change Breast Density, JNCI Journal of the National Cancer Institute, vol.95, issue.1, pp.4-5, 2003.
DOI : 10.1093/jnci/95.1.4

C. Campagnoli, C. Abbà, S. Ambroggio, N. Biglia, and R. Ponzone, Breast cancer and hormone replacement therapy: putting the risk into perspective, Gynecological Endocrinology, vol.62, issue.6, pp.53-60, 2001.
DOI : 10.3109/13697130009167593

R. D. Gambrell, R. C. Maier, and B. I. Sanders, Decreased incidence of breast cancer in postmenopausal estrogenprogestogen users, Obstet. Gynecol, vol.62, issue.3, pp.435-443, 1983.

P. Conner, G. Soderqvist, L. Skoog, T. Graser, F. Walter et al., Breast Cell Proliferation in Postmenopausal Women During HRT Evaluated Through Fine Needle Aspiration Cytology, Breast Cancer Research and Treatment, vol.283, issue.2, pp.159-165, 2003.
DOI : 10.1023/A:1022987618445

D. F. Hargreaves, F. Knox, R. Swindell, C. S. Potten, and N. J. Bundred, Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy, British Journal of Cancer, vol.78, issue.7, pp.945-949, 1998.
DOI : 10.1038/bjc.1998.606

P. D. Darney, The androgenicity of progestins, The American Journal of Medicine, vol.98, issue.1, pp.104-110, 1995.
DOI : 10.1016/S0002-9343(99)80067-9

A. E. Schindler, C. Campagnoli, R. Druckmann, J. Huber, J. R. Pasqualini et al., Classification and pharmacology of progestins, Maturitas, vol.46, issue.S1, pp.7-16, 2003.
DOI : 10.1016/j.maturitas.2003.09.014

J. M. Bentel, S. N. Birrell, M. A. Pickering, D. J. Holds, D. J. Horsfall et al., Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells, Molecular and Cellular Endocrinology, vol.154, issue.1-2, pp.1-2, 1999.
DOI : 10.1016/S0303-7207(99)00109-4

R. Kaaks, Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Contr, pp.605-625, 1996.

R. R. Kazer, Insulin resistance, insulin-like growth factor I and breast cancer: A hypothesis, International Journal of Cancer, vol.41, issue.4, pp.403-406, 1995.
DOI : 10.1002/ijc.2910620408

P. F. Bruning, J. M. Bonfrer, P. A. Van-noord, A. A. Hart, M. Jong-bakker et al., Insulin resistance and breast-cancer risk, International Journal of Cancer, vol.2, issue.4, pp.511-516, 1992.
DOI : 10.1002/ijc.2910520402

D. A. Lawlor, G. D. Smith, and . Ebrahim, Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women " s Heart and Health Study, Cancer Causes Contr, pp.267-275, 2004.

A. Malin, Q. Dai, H. Yu, X. O. Shu, F. Jin et al., Evaluation of the synergistic effect of insulin resistance and insulin-like growth factors on the risk of breast carcinoma, Cancer, vol.47, issue.4, pp.694-700, 2004.
DOI : 10.1002/cncr.20023

P. Muti, T. Quattrin, B. J. Grant, V. Krogh, A. Micheli et al., Fasting glucose is a risk factor for breast cancer: a prospective study, Cancer Epidemiol. Biomarkers Prev, vol.11, issue.11, pp.1361-1368, 2002.

C. Schairer, D. Hill, S. R. Sturgeon, T. Fears, M. Pollak et al., Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women, International Journal of Cancer, vol.10, issue.5, pp.773-779, 2004.
DOI : 10.1002/ijc.11624

J. E. Nestler and D. J. Jakubowicz, Decreases in Ovarian Cytochrome P450c17 alpha Activity and Serum Free Testosterone After Reduction of Insulin Secretion in Polycystic Ovary Syndrome, Obstetrical & Gynecological Survey, vol.52, issue.2, pp.617-623, 1996.
DOI : 10.1097/00006254-199702000-00017

L. Poretsky and M. F. Kalin, The Gonadotropic Function of Insulin*, Endocrine Reviews, vol.8, issue.2, pp.132-141, 1987.
DOI : 10.1210/edrv-8-2-132

F. Berrino, C. Bellati, S. Oldani, A. Mastroianni, G. Allegro et al., Nutrition and Lifestyle: Opportunities for Cancer Prevention, DIANA trials on diet and endogenous hormones, pp.439-444, 2002.

R. Kaaks, C. Bellati, E. Venturelli, S. Rinaldi, G. Secreto et al., Effect of dietary intervention on IGFI and IGF-binding proteins and related alterations in sex steroid metabolism: the Diet and Androgens (DIANA) Randomized Trial, Eur, J. Clin. Nutr, vol.57, issue.9, pp.1088-1979, 2003.

J. P. Thissen, J. M. Ketelslegers, and L. E. Underwood, Nutritional regulation of the insulin-like growth factors, Endocr. Rev, vol.15, issue.1, pp.80-101, 1994.

R. Kaaks and A. Lukanova, Energy balance and cancer: the role of insulin and insulin-like growth factor-I, Proceedings of the Nutrition Society, vol.42, issue.01, pp.91-106, 2001.
DOI : 10.1111/j.1365-2265.1984.tb00060.x

I. H. Hamelers and P. H. Steenbergh, Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells, Endocrine Related Cancer, vol.10, issue.2, pp.331-345, 2003.
DOI : 10.1677/erc.0.0100331

B. R. Westley and F. E. May, Role of insulin-like growth factors in steroid modulated proliferation, The Journal of Steroid Biochemistry and Molecular Biology, vol.51, issue.1-2, pp.1-2, 1994.
DOI : 10.1016/0960-0760(94)90109-0

M. N. Pollak, E. S. Schernhammer, and S. E. Hankinson, Insulin-like growth factors and neoplasia, Nature Reviews Cancer, vol.93, issue.7, pp.505-518, 2004.
DOI : 10.1126/science.1096706

A. G. Renehan, M. Zwahlen, C. Minder, S. T. O-"-dwyer, S. M. Shalet et al., Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis, The Lancet, vol.363, issue.9418, pp.1346-1353, 2004.
DOI : 10.1016/S0140-6736(04)16044-3

R. Kaaks, E. Lundin, S. Rinaldi, J. Manjer, C. Biessy et al., Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden, Cancer Causes Contr, pp.307-316, 2002.

F. Berrino, P. Muti, A. Micheli, G. Bolelli, V. Krogh et al., Serum Sex Hormone Levels After Menopause and Subsequent Breast Cancer, JNCI Journal of the National Cancer Institute, vol.88, issue.5, pp.291-296, 1996.
DOI : 10.1093/jnci/88.5.291
URL : http://jnci.oxfordjournals.org/cgi/content/short/88/5/291

N. Fortunati, M. Becchis, M. G. Catalano, A. Comba, P. Ferrera et al., Sex hormonebinding globulin, its membrane receptor, and breast cancer: a new approach to the modulation of estradiol action in neoplastic cells, J. Steroid Biochem. Mol. Biol, vol.69, pp.1-6, 1999.

B. Andersson, L. A. Mattsson, L. Hahn, P. Marin, L. Lapidus et al., Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulindependent diabetes mellitus, J. Clin. Endocrinol. Metab, vol.82, issue.2, pp.638-643, 1997.

U. J. Gaspard, J. M. Gottal, and F. A. Van-den-brule, Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects, Maturitas, vol.21, issue.3, pp.171-178, 1995.
DOI : 10.1016/0378-5122(95)00901-V

U. J. Gaspard, O. J. Wery, A. J. Scheen, C. Jaminet, and P. J. Lefebvre, Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women, Climacteric, vol.80, issue.2, pp.93-100, 1999.
DOI : 10.1210/jcem-72-3-642

S. R. Lindheim, S. C. Presser, E. C. Ditkoff, M. A. Vijod, F. Z. Stanczyk et al., A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin*, Fertility and Sterility, vol.60, issue.4, pp.664-667, 1993.
DOI : 10.1016/S0015-0282(16)56218-9

S. R. Lindheim, D. M. Duffy, T. Kojima, M. A. Vijod, F. Z. Stanczyk et al., The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women**Supported, in part, by the National Institutes of Health National Center for Research Resources of the General Clinical Research Centers grant M01 RR043, Bethesda, Maryland., Fertility and Sterility, vol.62, issue.6, pp.1176-1180, 1994.
DOI : 10.1016/S0015-0282(16)57181-7

K. L. Margolis, D. E. Bonds, R. J. Rodabough, L. Tinker, L. S. Phillips et al., Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women?s Health Initiative Hormone Trial, Diabetologia, vol.47, issue.7, pp.1175-1187, 2004.
DOI : 10.1007/s00125-004-1448-x

J. C. Stevenson, The metabolic and cardiovascular consequences of HRT, Br, J. Clin. Pract, vol.49, issue.2, pp.87-90, 1995.

C. Campagnoli, N. Biglia, C. Peris, and P. Sismondi, Potential impact on breast cancer risk of circulating insulin???like growth factor I modifications induced by oral HRT in menopause, Gynecological Endocrinology, vol.52, issue.1, pp.67-74, 1995.
DOI : 10.1210/edrv-11-2-266

C. Campagnoli, N. Biglia, P. Belforte, D. Botta, E. Pedrini et al., Post-menopausal breast cancer risk: oral estrogen treatment and abdominal obesity induce opposite changes in possibly important biological variables, Eur. J. Gynaecol. Oncol, vol.13, issue.2, pp.139-154, 1992.

C. Campagnoli, C. Abbà, S. Ambroggio, and C. , Differential effects of progestins on the circulating IGF-I system, Maturitas, vol.46, pp.39-44, 2003.
DOI : 10.1016/j.maturitas.2003.09.017

C. Campagnoli, S. Ambroggio, N. Biglia, and P. Sismondi, Conjugated estrogens and breast cancer risk, Gynecol. Endocrinol, vol.13, issue.S6, pp.13-19, 1999.

M. H. Jeng, C. J. Parker, and V. C. Jordan, Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation, Cancer Res, vol.52, issue.23, pp.6539-6546, 1992.

L. Markiewicz, R. B. Hochberg, and E. Gurpide, Intrinsic estrogenicity of some progestagenic drugs, The Journal of Steroid Biochemistry and Molecular Biology, vol.41, issue.1, pp.53-58, 1992.
DOI : 10.1016/0960-0760(92)90224-7

T. Rabe, M. K. Bohlmann, S. Rehberger-schneider, and S. Prifti, Induction of estrogen receptor-?? and -?? activities by synthetic progestins, Gynecological Endocrinology, vol.52, issue.2, pp.118-126, 2000.
DOI : 10.1002/cncr.2820710415

J. R. Pasqualini, G. Chetrite, C. Blacker, M. C. Feinstein, L. Delalonde et al., Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and postmenopausal breast cancer patients, J. Clin. Endocrinol. Metab, vol.81, issue.4, pp.1460-1464, 1996.

J. R. Pasqualini, Differential effects of progestins on breast tissue enzymes, Maturitas, vol.46, pp.45-54, 2003.
DOI : 10.1016/j.maturitas.2003.09.018

C. P. Spencer, I. F. Godsland, A. J. Cooper, D. Ross, M. I. Whitehead et al., Effects of oral and transdermal 17??-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women, Metabolism, vol.49, issue.6, pp.742-747, 2000.
DOI : 10.1053/meta.2000.6238

I. F. Godsland, K. Gangar, C. Walton, M. P. Cust, M. I. Whitehead et al., Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy, Metabolism, vol.42, issue.7, pp.846-853, 1993.
DOI : 10.1016/0026-0495(93)90058-V

K. E. Elkind-hirsch, L. D. Sherman, and R. Malinak, Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure, J. Clin. Endocrinol. Metab, vol.76, issue.2, pp.472-475, 1993.

C. Campagnoli, N. Biglia, M. G. Lanza, L. Lesca, C. Peris et al., Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report, Maturitas, vol.19, issue.1, pp.25-31, 1994.
DOI : 10.1016/0378-5122(94)90038-8

A. Heald, P. L. Selby, A. White, and J. M. Gibson, Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis, American Journal of Obstetrics and Gynecology, vol.183, issue.3, pp.593-600, 2000.
DOI : 10.1067/mob.2000.106994

A. G. Nugent, K. C. Leung, D. Sullivan, A. T. Reutens, and K. K. Ho, Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women, Clinical Endocrinology, vol.273, issue.6, pp.690-698, 2003.
DOI : 10.1016/S0140-6736(94)90181-3

M. F. Mccarty, Androgenic progestins amplify the breast cancer risk associated with hormone replacement therapy by boosting IGF-I activity, Medical Hypotheses, vol.56, issue.2, pp.213-216, 2001.
DOI : 10.1054/mehy.2000.1152

V. T. Miller, R. A. Muesing, J. C. Larosa, D. B. Stoy, E. A. Phillips et al., Effects of Conjugated Equine Estrogen With and Without Three Different Progestogens on Lipoproteins, High-Density Lipoprotein Subfractions, and Apolipoprotein A-I, Obstetrics & Gynecology, vol.77, issue.2, pp.235-240, 1991.
DOI : 10.1097/00006250-199102000-00014

K. Bakken, E. Alsaker, A. E. Eggen, and E. Lund, Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study, International Journal of Cancer, vol.112, issue.1, pp.130-134, 2004.
DOI : 10.1002/ijc.20389